Understanding the Mpox outbreak: Advances in epidemiology, management and prevention (Review)

Monkeypox (Mpox) is a zoonotic disease caused by the monkeypox virus (MPXV), a member of the <em>Poxviridae</em> family. Historically endemic to Central and West Africa, its spread beyond these regions in 2022 prompted the World Health Organization to declare it a public health emergency. Mpox is primarily transmitted through direct skin‑to‑skin contact with lesions, animal bites, or exposure to contaminated materials. The present review discusses the epidemiological, virological, immunological, clinical, diagnostic, and preventive aspects of Mpox infection. It highlights the two main viral clades (clade I and clade II), the role of APOBEC3‑driven mutations, and factors contributing to the resurgence of outbreaks, such as environmental changes, increased urbanization, air travel, and the prevalence of HIV/AIDS. Clinical manifestations range from localized rash and systemic symptoms to severe complications like encephalitis and sepsis. Diagnostic approaches including PCR, whole‑genome sequencing, and electron microscopy are explored, alongside preventive measures such as the JYNNEOS and ACAM2000 vaccines. Management primarily involves supportive care and antiviral therapy with tecovirimat, although recent clinical trials have raised concerns about its efficacy. Challenges in outbreak control include limited vaccine access, diagnostic resource gaps, stigma, particularly among high‑risk populations, and the potential emergence of antiviral resistance. The present review emphasizes the importance of the One Health approach, recognizing the interconnectedness of human, animal, and environmental health sectors, to ensure a coordinated and effective response. Furthermore, it underscores the need for ongoing research into viral evolution, novel therapeutic development, enhanced diagnostic methods, and understanding long‑term physical and psychosocial outcomes to strengthen global preparedness against Mpox outbreaks.